Autopsy report · NCT03645876
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
Cause of deathFunding or business
“The study was terminated early due to company decision”
Life of this trial
- Registered 3 months before it started.
- Ran for about 5 months before it stopped.
- 12 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- SHR-1210; BP102; oxaliplatin; capecitabine
- Participants
- 12
- Sites
- 1
- Countries
- China
Trials that died the same way
- Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
“This study was terminated early due to company decision.” - Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
“The study was terminated due to a business decision.” - Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
“Study terminated due to business and strategic decision.” - An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
“Study was prematurely terminated due to administrative and strategic reasons” - An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths
“Due to a business decision to stop the project, the study was terminated early.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.